Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$25.92 USD
+1.46 (5.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $25.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLDX 25.92 +1.46(5.97%)
Will CLDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Other News for CLDX
Is CLDX setting up for a drop? Shooting Star Candlestick shows up after sliding 0.49%
Celldex (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in CSU
Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
Celldex's barzo shows strong efficacy in CSU patients, says H.C. Wainwright